Voveran SR

Product Overview

Voveran SR is a sustained-release medication containing Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). Designed for prolonged therapeutic effect, these tablets gradually release the active ingredient to deliver extended pain relief and anti-inflammatory action. The sustained-release mechanism maintains consistent drug levels while minimizing dosing frequency. Clinically prescribed for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other inflammatory conditions, this formulation offers advantages over immediate-release versions through its prolonged duration of action.

Therapeutic Applications

This medication is clinically indicated for managing pain and inflammation in both acute and chronic musculoskeletal disorders. Its extended-release profile makes it particularly suitable for patients requiring continuous symptom control, offering the convenience of single daily administration. By effectively reducing inflammatory mediators, Voveran SR helps alleviate discomfort, decrease swelling, and enhance joint mobility, thereby improving patients’ functional capacity and quality of life.

Administration Guidelines

For optimal results, swallow Voveran SR tablets intact with sufficient water, preferably during meals to mitigate potential gastric irritation. The tablet’s structural integrity must be maintained – crushing, chewing, or splitting compromises its controlled-release mechanism. Adhere strictly to prescribed dosing schedules. In case of missed dose, take at earliest opportunity unless approaching next scheduled dose; never compensate with double dosing.

Mechanism of Action

The pharmacological activity stems from selective inhibition of cyclooxygenase enzymes (COX-1 and COX-2), thereby suppressing prostaglandin biosynthesis. These lipid mediators play key roles in inflammatory pathways, pain perception, and fever response. The sustained-release matrix ensures gradual diclofenac liberation, maintaining therapeutic plasma concentrations for approximately 24 hours while minimizing peak-trough fluctuations characteristic of conventional formulations.

Dosage Protocol

Standard initial dosing typically involves 100mg once daily, adjusted based on therapeutic response and tolerability. Maximum daily intake should not exceed 150mg. Administration with food enhances gastrointestinal tolerance. Special populations (elderly, hepatic/renal impairment) may require dose modifications. Tablets must be swallowed whole to preserve their extended-release characteristics. Regular medical supervision ensures optimal dosing regimen maintenance.

Therapeutic Advantages

The sustained-release formulation provides multiple clinical benefits including simplified dosing schedules, improved medication adherence, and stable analgesic coverage. By maintaining consistent plasma concentrations, it prevents the breakthrough pain often experienced with shorter-acting formulations. This pharmacokinetic profile makes it particularly valuable for chronic inflammatory conditions requiring prolonged therapy, while reducing administration frequency enhances patient convenience.

Adverse Effects

Common adverse reactions predominantly involve the gastrointestinal system (dyspepsia, epigastric discomfort, nausea). Most are mild and self-limiting. Serious but rare complications include peptic ulceration, hepatotoxicity, renal impairment, and cardiovascular events. Hypersensitivity reactions may manifest as cutaneous eruptions or bronchospasm. Prompt medical attention is warranted for severe or persistent symptoms, particularly hematemesis, jaundice, or edema.

Precautions and Contraindications

Absolute contraindications include NSAID hypersensitivity, active peptic ulceration, and severe cardiac/hepatic/renal dysfunction. Caution is advised in patients with hypertension, fluid retention, or coagulation disorders. Concomitant alcohol use exacerbates gastrointestinal risks. Elderly patients require careful monitoring due to increased susceptibility to adverse effects. Cardiovascular risk assessment is recommended before prolonged therapy initiation.

Storage Requirements

Maintain at controlled room temperature (15-30°C) in original packaging, protected from humidity and light exposure. Improper storage in moist environments (bathrooms) may compromise tablet integrity. Keep securely closed and out of children’s reach. Dispose expired or unused medication through authorized take-back programs; avoid environmental contamination via toilet disposal.

Medical Disclaimer

While we strive to provide accurate, evidence-based information, this content serves educational purposes only and does not substitute professional medical advice. Pharmaceutical knowledge continuously evolves; therefore consult your healthcare provider for personalized guidance regarding therapeutic options, potential interactions, or emerging safety concerns. This information aims to facilitate informed patient-physician discussions, not replace clinical judgment. Always disclose complete medical history and concurrent medications to your treating physician.